<DOC>
	<DOC>NCT01613326</DOC>
	<brief_summary>This study compared the efficacy and safety of NVA237 with tiotropium in patients with moderate to severe COPD. Tiotropium belongs to the same drug class as NVA237.</brief_summary>
	<brief_title>Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>This was a randomized, blinded, double-dummy, parallel-group 12-week study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients with chronic obstructive pulmonary disease (COPD).</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patients with moderate to severe stable COPD (Stage II or Stage III) according to the current GOLD Guidelines (GOLD 2010). Patients with a postbronchodilator Forced Expiratory Volume in 1 second (FEV1) ≥ 30% and &lt; 80% of the predicted normal, and a postbronchodilator FEV1/ Forced Vital Capacity (FVC) &lt; 0.70 at screening Current or exsmokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1 pack/day x 10 yrs, or ½ pack/day x 20 yrs). Symptomatic patients, according to daily electronic diary data between Visit 2 (Day 14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to Visit 3. Pregnant or nursing (lactating) women Patients who, in the judgment of the investigator, or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition before Visit 1. Patients with narrowangle glaucoma, symptomatic benign prostatic hyperplasia or bladderneck obstruction or moderate to severe renal impairment or urinary retention. (BPH patients who are stable on treatment can be considered). Patients receiving medications in the classes listed in the protocol as prohibited. Other protocoldefined inclusion/exclusion criteria apply and can be found in the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>COPD</keyword>
</DOC>